KIT and acute myeloid leukemia: Similarly, WNT974 reduced the in vitro replating capacity of CD117+ LSC derived from MllPTD/WT/Flt3ITD/WT mice (a potent in vivo model of AML [125]) but did not significantly impact engraftment or survival in vivo suggesting combinatorial approaches might be required.